Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 26, 2013Clinical Cancer Research

Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2 : A Report by MSKCC and the KIRC TCGA Research Network

View Full Paper
Ask AI
Bookmark
Share

Authors

AHA. Ari HakimiPenn State Milton S. Hershey Medical CenterIOIrina OstrovnayaMemorial Sloan Kettering Cancer CenterBRBoris RevaIcahn School of Medicine at Mount Sinai

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hakimi et al. (2013) studied this question.

synapsesocial.com/papers/69dc34d445b398e6439f5599https://doi.org/10.1158/1078-0432.ccr-12-3886
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A POSTOPERATIVE PROGNOSTIC NOMOGRAM PREDICTING RECURRENCE FOR PATIENTS WITH CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA2005 · 533 citations
  2. 2An Outcome Prediction Model for Patients with Clear Cell Renal Cell Carcinoma Treated with Radical Nephrectomy Based on Tumor Stage, Size, Grade and Necrosis: The Ssign Score2002 · 1,149 citations
  3. 3Cancer statistics, 20122012 · 10,721 citations